Gymconopin C fights lung cancer via miR-6777-5p/ADRB2-mediated mitophagy

A compound extracted from a traditional Chinese medicinal herb long prized for stopping hemorrhages may offer a strikingly effective new weapon against non-small cell lung cancer, according to a study published in the Journal of Advanced Research. The compound, known as Gymconopin C, was isolated from Bletilla striata, an orchid used for centuries in Chinese medicine, and researchers report that it kills lung cancer cells more potently than cisplatin—one of the most widely used chemotherapy drugs—while causing significantly less damage to healthy tissue in animal models.

The numbers behind the research underscore why new treatments are so urgently needed. According to China’s National Cancer Center, more than 1.06 million new lung cancer cases were recorded in 2022, with 733,300 deaths, making lung cancer the deadliest malignancy in the country. Non-small cell lung cancer (NSCLC) accounts for roughly 85 percent of those cases, and because most patients are diagnosed at advanced stages, the five-year survival rate remains below 18 percent. Surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy all carry substantial toxicities, and drug resistance erodes their effectiveness over time. Against this backdrop, the search for natural compounds with defined molecular targets has intensified.

Led by Xue Li and Fu Peng of Sichuan University, together with colleagues at Chengdu University of Traditional Chinese Medicine and other institutions, the research team systematically tested Gymconopin C against two human NSCLC cell lines, A549 and NCI-H1299. In cell viability assays, the compound achieved half-maximal inhibitory concentrations (IC50) of 5.642 micromolar at 24 hours and 2.767 micromolar at 48 hours in A549 cells, and 2.047 and 1.152 micromolar respectively in NCI-H1299 cells. Cisplatin, by comparison, required 18.230 and 9.902 micromolar in A549 cells over the same periods—meaning Gymconopin C was several times more effective at suppressing cancer cell proliferation. Colony formation assays confirmed that treated cells lost their ability to form new colonies, while wound-healing and Transwell experiments showed that migration and invasion through artificial basement membranes were sharply curtailed.

At the molecular level, the compound appeared to sabotage the metastatic machinery of the cancer cells. Epithelial-mesenchymal transition, or EMT, is the process by which tumor cells shed their epithelial identity and adopt the mobile, invasive characteristics of mesenchymal cells. Gymconopin C reversed the hallmark “cadherin switch,” reducing levels of N-cadherin and vimentin while restoring E-cadherin. It also strengthened intercellular junctions by increasing the tight-junction proteins ZO-1 and claudin-1, and it suppressed the matrix-degrading enzymes MMP-2 and MMP-7, which tumors use to chew through surrounding tissue.

Flow cytometry revealed a second mechanism of attack: cell cycle arrest. After Gymconopin C treatment, the fraction of A549 cells trapped in the G2 phase of the cell cycle surged from just over 9 percent to more than 51 percent at higher doses. The compound reduced expression of the G2 regulatory proteins CDC25C, cyclin B1 and CDK1, blocking the transition needed for cells to divide. Simultaneously, apoptosis rose markedly, with pro-death proteins Bax and cleaved caspase-3 climbing while the anti-apoptotic protein survivin declined.

But the most consequential discovery involved mitochondria. Transmission electron microscopy of treated cells revealed profound mitochondrial damage—dissolution of the cristae that house the machinery of cellular respiration—alongside numerous autophagic vesicles and autolysosomes. The compound was triggering mitophagy, the selective autophagic removal of damaged mitochondria. While moderate mitophagy helps tumor cells maintain their metabolism, excessive mitophagy can cause catastrophic bioenergetic collapse. When the researchers co-treated cells with Mdivi-1, a chemical inhibitor of mitophagy, the cancer-killing effect of Gymconopin C was substantially blunted—direct evidence that the compound works by pushing mitochondrial destruction past a lethal threshold.

The downstream consequences were consistent with this model. Gymconopin C-treated cells accumulated reactive oxygen species and mitochondrial superoxide, their mitochondrial membrane potential collapsed as measured by JC-1 staining, and both ATP production and mitochondrial DNA copy number fell significantly. Senescence-associated beta-galactosidase staining showed the cells entering a senescent state. Protein analysis confirmed activation of the canonical PINK1/Parkin mitophagy pathway: levels of LC3B-II, BNIP3, PINK1 and Parkin rose, while mitochondrial structural proteins TIM23, TOM20 and VDAC1—markers of surviving mitochondria—were depleted.

To identify how the compound initiates this cascade, the team turned to whole-transcriptome sequencing. Among 156 differentially expressed microRNAs, one stood out: hsa-miR-6777-5p, the most strongly downregulated miRNA after treatment. Database analyses using CancerMIRNome and dbDEMC showed that this miRNA is elevated in NSCLC and that high levels correlate with poorer survival, marking it as an oncogene. Molecular docking predicted that Gymconopin C binds directly to miR-6777-5p through hydrogen bonds and π-hydrogen interactions, with a favorable binding energy score of −5.3844 kcal/mol, suggesting the compound may physically occupy the miRNA’s functional domain and disable it.

The researchers then traced the pathway downstream. Cross-referencing predicted targets of miR-6777-5p from the miRDB, TargetScan and miRWalk databases with genes upregulated by the drug, they identified ADRB2—the beta-2 adrenergic receptor—as a key target. RNA immunoprecipitation experiments confirmed that miR-6777-5p binds ADRB2 messenger RNA via the Ago2 protein complex, and that suppressing the miRNA releases ADRB2 expression. Functional tests sealed the loop: overexpressing miR-6777-5p promoted cancer cell proliferation, migration and invasion while suppressing mitophagy, whereas knocking down ADRB2 had similar pro-tumor effects. Conversely, forcing ADRB2 expression halted proliferation and enhanced PINK1/Parkin-mediated mitophagy—an effect reversed by miR-6777-5p. Prior research had shown ADRB2 activation boosts LC3B and Parkin expression, and clinical data indicate low ADRB2 levels predict poor survival in lung adenocarcinoma, consistent with its role as a tumor suppressor here.

The in vivo results were equally compelling. In BALB/C nude mice bearing A549 xenograft tumors, daily intraperitoneal Gymconopin C at 18 mg/kg for 25 days significantly shrank tumor volume and weight, reduced the proliferation marker Ki-67 in tumor tissue, and elevated LC3B, Parkin and ADRB2 levels—mirroring the in vitro findings. Critically, the safety profile favored the natural compound. Mice receiving cisplatin lost weight, showed anorexia and reduced mobility, and suffered measurable spleen and kidney damage with elevated blood urea nitrogen. Gymconopin C-treated animals maintained stable body weight and normal organ architecture on histological examination, with liver and kidney function indicators indistinguishable from healthy controls.

A third model added an innovative dimension. The team transplanted fluorescently labeled human cancer cells into zebrafish larvae, a rapid and ethically lighter system for drug screening. Gymconopin C showed dose-dependent anti-tumor activity with a maximum tolerated dose of 100 ng per fish and an LD50 of 185 ng, demonstrating a wide therapeutic window. When the researchers engineered zebrafish tumors overexpressing miR-6777-5p, tumor cells proliferated aggressively—but Gymconopin C neutralized the effect, shrinking fluorescent tumor signals and reducing invasion. This confirmed in a living vertebrate that the miRNA is a genuine functional target of the drug.

The authors caution that the miR-6777-5p/ADRB2 axis was validated primarily in A549 cells, and that its generalizability across the molecularly diverse landscape of NSCLC subtypes—driven by mutations in EGFR, KRAS, ALK and ROS1—will require further study. The direct physical binding between the compound and the miRNA also remains a computational prediction pending biophysical confirmation. Even so, the study delivers something rare for a natural product: a complete mechanistic chain from chemical structure to molecular target to cellular pathway to animal efficacy, with safety data suggesting a therapeutic margin wider than that of standard platinum chemotherapy.

If subsequent development confirms these results, Gymconopin C could represent a new class of anti-cancer agents that weaponize mitophagy against tumors—and a vindication of traditional Chinese medicine as a source of structurally novel drugs with precisely defined mechanisms of action.